Status:
COMPLETED
Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis
Lead Sponsor:
Gilead Sciences
Conditions:
Bronchiectasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Over the 70-day study period, eligible patients visited the study clinic every 2 weeks (total of 6 visits) and received a 28-day course of aztreonam for inhalation solution (AZLI). The Quality of Life...
Eligibility Criteria
Inclusion
- Written informed consent prior to any study-related procedures
- Ability to read and understand the English language
- Bronchiectasis confirmed by CT scan of the chest
- Previous treatment with antibiotics for bronchiectasis
- Documented history of positive sputum culture for a gram-negative organism within 5 years
- Positive sputum culture for a gram-negative organism at first visit (Day -14)
Exclusion
- Hospitalization or hemoptysis \> 30 mL within 14 days of first visit (Day -14)
- Antibiotic use for respiratory symptoms within 14 days of first visit (Day -14), excluding chronic, stable azithromycin use
- Change in corticosteroid or bronchodilator regimen within 14 days of first visit (Day -14)
- Forced expiratory volume in 1 second (FEV1) \< 25% predicted approximately 15 minutes following use of a bronchodilator at first visit (Day -14)
- Cigarette smoking within 6 months of first visit (Day -14)
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT00805025
Start Date
December 1 2008
End Date
October 1 2009
Last Update
March 20 2014
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35209
2
Peoria, Arizona, United States, 85381
3
Phoenix, Arizona, United States, 85006
4
Orange, California, United States, 92868